Company intelligence / Profile preview
Taiwan Bio Therapeutics
Zhubei City, Hsinchu County, Taiwantwbio-thera.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Taiwan Bio Therapeutics is a clinical-stage biotech specializing in engineered allogeneic cell therapies, particularly mesenchymal stem cells and regulatory T cells. Its lead program, TregCel, is entering global Phase 2 trials for prevention of kidney transplant rejection. Other pipeline assets target osteoarthritis, lower limb ischemia, acute myocardial infarction, and frailty syndrome. The company also provides CDMO services to other developers. Recent results include TFDA approval to initiate a Phase II trial for TRK‑001/TregCel with patient enrollment underway in both Taiwan and the US as of early 2025. The company reported record revenue growth from its CDMO business but remains unprofitable due to high R&D investment.
- Therapeutic areas
- OtherImmunologyCardiovascularRheumatology
- Modalities
- Cell therapyMesenchymal stem cell therapyRegulatory T cell therapy (Treg)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Mayo Clinic – strategic alliance for next-generation cell therapies/manufacturing hub in Phoenix, AZTRACT Therapeutics – technology transfer/collaboration on regulatory T-cell platform
Beyond the preview
Go deeper on Taiwan Bio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taiwan Bio Therapeutics.